Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products, as well as medical supplies. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; offers pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression solution, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Additionally, it manufactures, prepares, delivers, and distributes radiopharmaceuticals and related treatments; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Cardinal Health Inc.

In a report released yesterday, Jonathan Sharp from J.P. Morgan maintained a Buy rating on Evolution Mining , with a price target of A$15.00. Accor...

J.P. Morgan Remains a Buy on Evolution Mining  (CAHPF)

Markets React to Oil, Risk, and Rotation U.S. stocks moved lower last week as war risk and rising oil prices weighed on sentiment. The S&P 500 (SPX...

The Week That Was, The Week Ahead: Macro and Markets, Mar. 29

In a report released today, Levi Spry from UBS upgraded Evolution Mining to a Hold, with a price target of A$12.50. According to TipRanks, Spry is ...

Evolution Mining  (CAHPF) was upgraded to a Hold Rating at UBS

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Orchestra BioMed Holdings (OBIO – Research Report), ...

Analysts’ Top Healthcare Picks: Orchestra BioMed Holdings (OBIO), Cardinal Health (CAH)

In a report released today, Levi Spry from UBS maintained a Sell rating on Evolution Mining , with a price target of A$12.80. According to TipRanks...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CAH	$214.05	0.00%	1.50M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CAH	$214.05	0%	1.50M
3
4
5
6

CAH

CAH

Get Cardinal Health Inc. Data in Excel

Get Cardinal Health Inc. Data in Excel